Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 May;18(5):587-598.
doi: 10.1016/j.jtho.2022.12.019. Epub 2023 Jan 13.

Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

Laurent Dercle  1 , Matthew Fronheiser  2 , Naiyer A Rizvi  3 , Matthew D Hellmann  4 , Sabine Maier  2 , Wendy Hayes  2 , Hao Yang  3 , Pingzhen Guo  3 , Tito Fojo  3 , Lawrence H Schwartz  3 , Binsheng Zhao  3 , David K Leung  2
Affiliations
Free article
Randomized Controlled Trial

Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

Laurent Dercle et al. J Thorac Oncol. 2023 May.
Free article

Abstract

Introduction: We aimed to define a baseline radiomic signature associated with overall survival (OS) using baseline computed tomography (CT) images obtained from patients with NSCLC treated with nivolumab or chemotherapy.

Methods: The radiomic signature was developed in patients with NSCLC treated with nivolumab in CheckMate-017, -026, and -063. Nivolumab-treated patients were pooled and randomized to training, calibration, or validation sets using a 2:1:1 ratio. From baseline CT images, volume of tumor lesions was semiautomatically segmented, and 38 radiomic variables depicting tumor phenotype were extracted. Association between the radiomic signature and OS was assessed in the nivolumab-treated (validation set) and chemotherapy-treated (test set) patients in these studies.

Results: A baseline radiomic signature was identified using CT images obtained from 758 patients. The radiomic signature used a combination of imaging variables (spatial correlation, tumor volume in the liver, and tumor volume in the mediastinal lymph nodes) to output a continuous value, ranging from 0 to 1 (from most to least favorable estimated OS). Given a threshold of 0.55, the sensitivity and specificity of the radiomic signature for predicting 3-month OS were 86% and 77.8%, respectively. The signature was identified in the training set of patients treated with nivolumab and was significantly associated (p < 0.0001) with OS in patients treated with nivolumab or chemotherapy.

Conclusions: The radiomic signature provides an early readout of the anticipated OS in patients with NSCLC treated with nivolumab or chemotherapy. This could provide important prognostic information and may support risk stratification in clinical trials.

Keywords: Computed tomography; Non–small cell lung cancer; Overall survival; Radiomic.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

Publication types

MeSH terms